ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics PLC (ADAP)

1.08
-0.03
( -2.70% )
Updated: 10:50:14

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
1.08
Bid
1.07
Ask
1.09
Volume
237,341
1.06 Day's Range 1.12
0.00 52 Week Range 0.00
Market Cap
Previous Close
1.11
Open
1.12
Last Trade
10
@
1.08
Last Trade Time
10:51:23
Financial Volume
$ 258,131
VWAP
1.0876
Average Volume (3m)
-
Shares Outstanding
1,363,008,000
Dividend Yield
-
PE Ratio
-12.81
Earnings Per Share (EPS)
-0.08
Revenue
60.28M
Net Profit
-113.87M

About Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell r... Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, NON-SMALL CELL LUNG CANCER, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Oxfordshire, Gbr
Founded
1970
Adaptimmune Therapeutics PLC is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ADAP. The last closing price for Adaptimmune Therapeutics was $1.11. Over the last year, Adaptimmune Therapeutics shares have traded in a share price range of $ 0.00 to $ 0.00.

Adaptimmune Therapeutics currently has 1,363,008,000 shares outstanding. The market capitalization of Adaptimmune Therapeutics is $1.46 billion. Adaptimmune Therapeutics has a price to earnings ratio (PE ratio) of -12.81.

ADAP Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MMVMultiMetaVerse Holdings Ltd
$ 1.8801
(218.23%)
70.96M
GTBPGT Biopharma Inc
$ 7.31
(134.29%)
32.16M
TANHTantech Holdings Ltd
$ 1.286
(95.74%)
40.96M
FFIEFaraday Future Intelligent Electric Inc
$ 1.79
(73.79%)
334.15M
NKGNNKGen Biotech Inc
$ 1.81
(61.61%)
18.89M
AKTSAkoustis Technologies Inc
$ 0.1828
(-48.68%)
8.6M
VIRIVirios Therapeutics Inc
$ 0.1822
(-48.15%)
2.16M
MTCMMTec Inc
$ 3.81
(-45.65%)
4.51M
JAGXJaguar Health Inc
$ 0.146424
(-43.36%)
28.18M
FLJFLJ Group Limited
$ 0.9548
(-38.40%)
2.97M
CRKNCrown Electrokinetics Corporation
$ 0.20805
(21.67%)
425.69M
FFIEFaraday Future Intelligent Electric Inc
$ 1.79
(73.79%)
334.15M
GWAVGreenwave Technology Solutions Inc
$ 0.1464
(-5.00%)
191.85M
MMVMultiMetaVerse Holdings Ltd
$ 1.8801
(218.23%)
70.96M
SINTSiNtx Technologies Inc
$ 0.1081
(27.18%)
66.25M

ADAP Discussion

View Posts
glenn1919 glenn1919 2 weeks ago
ADAP...................................https://stockcharts.com/h-sc/ui?s=ADAP&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
NY1972 NY1972 1 month ago
ADC is the future for solid tumors, no wait time, decent ORR. Why bother with TCR-T and deal with matching HLA, long wait and PD1 for persistence. All the CARNK bios are pivoting to SLE ....Will ADAP try a TCR-T + mAb combo or TCT-T + CBNK to improve ORR? Can 1 accountant innovate?
πŸ‘οΈ0
jondoeuk jondoeuk 1 month ago
The question remains, was it due to a refocused R&D strategy or data driven.
πŸ‘οΈ0
jondoeuk jondoeuk 1 month ago
Upcoming Investor Day (Apr 18, 8:00 am EDT) https://adaptimmune.zoom.us/webinar/register/WN_SAFMQyw3QbiyM9wSLIaTqw#/registration
πŸ‘οΈ0
jondoeuk jondoeuk 1 month ago
The multi-year strategic collaboration they struck with RHHBY's Genentech has been terminated. The agreement, established initially for eight years, aimed at launching cell therapies for various cancer indications using ADAP's iPSC platform. Per the terms, ADAP received $150M upfront and was expected to receive $150M in additional payments over five years. ADAP was also eligible to receive development and other milestone-based payments totalling as much as $3B.

https://finance.yahoo.com/news/strategic-collaboration-between-adaptimmune-genentech-120000529.html
πŸ‘οΈ0
jondoeuk jondoeuk 1 month ago
There is going to be clinical data from LYEL, CRSP and Arsenal Bio* over the next few years that could show if T-cell ''exhaustion'' can be overcome.

* The synthetic pathway activators that Arsenal Bio have created help with maintenance of T-cell stem-like phenotypes, and restrict accessibility of various exhaustion marker genes

πŸ‘οΈ0
Monksdream Monksdream 2 months ago
ADAP under $2
πŸ‘οΈ0
glenn1919 glenn1919 2 months ago
ADAP.......................................................................https://stockcharts.com/h-sc/ui?s=ADAP&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 2 months ago
ADAP...BIO MONSTER COMING IN HERE
πŸ‘οΈ0
Monksdream Monksdream 2 months ago
ADAP new 52 week high
πŸ‘οΈ0
glenn1919 glenn1919 3 months ago
ADAP.............................................https://stockcharts.com/h-sc/ui?s=ADAP&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
ADAP under $2
πŸ‘οΈ0
NY1972 NY1972 3 months ago
This explains why TIL, TCR-T, Tigit, ... not working. Exhausted T is a misnomer
https://www.cell.com/cell-reports/fulltext/S2211-1247(24)00040-8?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2211124724000408%3Fshowall%3Dtrue
πŸ‘οΈ0
1hot toddy 1hot toddy 3 months ago
WOOOOW 27000 SHARE BUY $$$$$$$$$$$
πŸ‘οΈ0
subslover subslover 4 months ago
Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review
Newsfile Corp.
Newsfile Corp
If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for synovial sarcoma in more than a decade
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 31, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its Biologics License Application (BLA) for afami-cel, an investigational engineered T-cell therapy for advanced synovial sarcoma. The application has a Prescription Drug User Fee Act (PDUFA) target action date of August 4, 2024.

Adrian Rawcliffe, Adaptimmune's Chief Executive Officer: β€œThe FDA’s acceptance of the BLA submission brings us one step closer to redefining treatment for people with synovial sarcoma. Our franchise has great potential and, if approved, we have the capabilities and the capital to launch afami-cel - the first engineered T-cell therapy on the market for a solid tumor cancer.”

Dennis Williams, PharmD, Senior VP of Late-Stage Development: "Historic outcomes are poor for advanced synovial sarcoma, with low objective response rates for second-line therapies and overall survival of less than 12 months for people who have received two or more prior lines of therapy. In clinical trials, afami-cel has demonstrated an impressive response rate of ~39% among heavily pre-treated patients with advanced synovial sarcoma and about a 17-month median survival. This regulatory milestone is a testament to our teams' relentless work to deliver a novel treatment option to more people diagnosed with synovial sarcoma."

This acceptance is supported by positive data from Cohort 1 of the pivotal trial SPEARHEAD-1, which met its primary endpoint for efficacy. Data from the trial were presented at the Connective Tissue Oncology Society (CTOS) 2023 Annual Meeting.
πŸ‘οΈ0
NY1972 NY1972 4 months ago
when was the last time the mgt. didn't missed a milestone promised. BLA, PRAME, ...
πŸ‘οΈ0
jondoeuk jondoeuk 4 months ago
Hard to say, but they have only talked about sequential/combination treatment with afami-cel and lete-cel, not committed to it. Based on what others are doing, I would like them to pick up the pass of innovation. Based on their own data, a TGF-B signature was measured across tumour indications, so think they should test the combination of NY-ESO-1 with MAGE-A4 TCRs that co-express the CD8a co-receptor with a dnTGF-BRII as well. They also ran a sub-study testing afami-cel with low-dose radiation. While small, it did show greater detection of SPEAR T-cells in tumour biopsies when infusion followed it. As for TC-520 (targeting CD70), I think it should be dropped.
πŸ‘οΈ0
NY1972 NY1972 4 months ago
May be the investors realized that CART, CARNK targeting single antigen not going to subdue solid cancers. Will 2nd gen SPEAR cells NY-ESO + MAGE-A4 combo or extracellular CD70 + SPEAR T cells combo avoid the CAR crash?
πŸ‘οΈ0
jondoeuk jondoeuk 4 months ago
Has the CEO finally awoken?!

''Sarcoma franchise of afami-cel and lete-cel leverages same development and commercial footprint with US peak year sales projected to be up to $400 million

BLA submitted in 2023 for afami-cel; projected acceptance by US FDA in Q1 2024

Company preparing for US launch of afami-cel in 2H 2024 upon expected approval

Pivotal trial for lete-cel met its primary endpoint for efficacy; full data set
in Q3 2024

Company working toward approval of lete-cel; planning for US commercial launch in 2026

Company funded into early 2026 with > $300 million including existing balance sheet, projected payments from partners, and other non-dilutive capital sources'' https://finance.yahoo.com/news/adaptimmune-projects-sarcoma-franchise-deliver-123700704.html
πŸ‘οΈ0
NY1972 NY1972 5 months ago
CARTs, ADCs not investable. Too many to count. Targeted bombing offers no OS benefits but long term health issues, secondary cancers and infections.
πŸ‘οΈ0
sc00pnDump sc00pnDump 5 months ago
https://www.managedhealthcareexecutive.com/view/adaptimmune-completes-bla-for-cell-therapy-for-solid-tumors
πŸ‘οΈ0
jondoeuk jondoeuk 5 months ago
Hard to say, but in the next few I expect to see datasets from others trials (testing ADCs) in platinum-resistant ovarian. However, there are downsides including, TEAEs, such as those leading to drug discontinuation, interruption or reduction. Also, dosing every 'x' amount of weeks.
πŸ‘οΈ0
Monksdream Monksdream 6 months ago
ADAP new 52 week low
πŸ‘οΈ0
sc00pnDump sc00pnDump 6 months ago
Very nice read

Thanks for posting
πŸ‘οΈ0
jondoeuk jondoeuk 6 months ago
The PR https://finance.yahoo.com/news/adaptimmune-reports-positive-data-lete-120000366.html

PDF https://d1io3yog0oux5.cloudfront.net/_344920efd0af3676fab777bf7e089512/adaptimmune/files/pages/adaptimmune/db/336/description/ny-eso-1/IGNYTE_substudy-1_CTOS23.pdf
πŸ‘οΈ0
jondoeuk jondoeuk 6 months ago
I wonder why they no longer talk about overexpression of PDE4C or PDE7A (the latter increases the ability to induce apoptosis in target cells, confers (partial) resistance to the inhibitory effects of forskolin, PGE2 and adenosine, as well as (partially) resistance to the inhibition of cytokine release by mediators that increase intracellular cAMP). Also, inducible IL-7 and inducible IL-15
πŸ‘οΈ0
jondoeuk jondoeuk 6 months ago
https://www.biospace.com/article/releases/adaptimmune-selects-adp-600-as-clinical-candidate-for-best-in-class-prame-strategy/

They should have taken a next-gen version* into the clinic instead. This is based on where IMTX is and the data generated to date https://investors.immatics.com/static-files/138d7b76-d252-4c61-a824-e17307c4f537

* I think it should include a CD8a co-receptor and dominant-negative TGF-B receptor https://journals.aai.org/jimmunol/article/208/1/169/234163/Engineering-Cancer-Antigen-Specific-T-Cells-to
πŸ‘οΈ0
Monksdream Monksdream 6 months ago
ADAP new 52 week low
πŸ‘οΈ0
jondoeuk jondoeuk 7 months ago
Preclinical https://link.springer.com/article/10.1007/s00262-023-03556-7
πŸ‘οΈ0
jondoeuk jondoeuk 7 months ago
New NY-ESO-1 data https://ctos2023.eventscribe.net/index.asp?posterTarget=604312





πŸ‘οΈ0
NY1972 NY1972 7 months ago
This is not good enough to survive the ADC tsunami.
35.6% (2 complete response, 14 partial response [PR]). Median duration of response was 20.79 weeks (95%CI: 11.6, 30.9)
πŸ‘οΈ0
Monksdream Monksdream 7 months ago
ADAP new 52 week low
πŸ‘οΈ0
jondoeuk jondoeuk 7 months ago
The ESMO abstract

1019O - Clinical and translational data from the phase I SURPASS trial of ADP-A2M4CD8 T cell receptor (TCR) T cell therapy alone or combined with nivolumab in solid tumors

Background
ADP-A2M4CD8 is a TCR T-cell therapy targeting melanoma-associated antigen A4 (MAGE-A4), modified with a CD8a coreceptor, to treat human leukocyte antigen A*02–eligible patients (pts) with unresectable/metastatic solid tumors. ADP-A2M4CD8 monotherapy has demonstrated an acceptable benefit-to-risk profile and encouraging anti-tumor activity in the ongoing phase 1 SURPASS trial. Nevertheless, inhibition of immunosuppressive pathways may improve anti-tumor responses; therefore, new SURPASS cohorts include ADP-A2M4CD8 combined with nivolumab or pembrolizumab. We report data from pts receiving monotherapy and nivolumab combination therapy.

Methods
T-cells are obtained by leukapheresis, transduced with a lentiviral vector carrying the TCR and CD8a coreceptor genes, expanded ex vivo, and infused back to the pt following lymphodepleting chemotherapy. ~Four weeks after ADP-A2M4CD8 infusion, a subset of pts also received nivolumab 480 mg every 4 weeks until unacceptable toxicity/disease progression. Primary and secondary objectives are safety and anti-tumor activity, respectively.

Results
As of March 9, 2023, 51 pts with a median age of 60 years (range: 31–75) mainly with melanoma, non-small cell lung, ovarian, gastroesophageal, head and neck, or urothelial cancers received 1.02–9.95x109 ADP-A2M4CD8 T-cells. Median (range) number of prior lines of therapy was 3 (1–8) and MAGE-A4 expression H-score was 250 (90–300). The four most common adverse events related to T-cell therapy were cytokine release syndrome (n=38 [74.5%]; 7 [13.7%] were Grade≥3), neutropenia (27.5%), pyrexia and fatigue (each 21.6%). Overall response rate per RECIST v1.1 by investigator review in monotherapy pts (n=45) was 35.6% (2 complete response, 14 partial response [PR]). Median duration of response was 20.79 weeks (95%CI: 11.6, 30.9). In pts assigned to nivolumab combination (n=6), there was 1 PR, 3 stable disease, and 2 not evaluable (2 pts have not received nivolumab and have no post-baseline RECIST assessment). Data from additional pts treated by August 2023 will be presented.

Conclusions
ADP-A2M4CD8 continues to show an acceptable benefit-to-risk profile, including in pts receiving nivolumab combination therapy.
πŸ‘οΈ0
Monksdream Monksdream 7 months ago
ADAP new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 8 months ago
ADAP new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 9 months ago
ADAP new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 9 months ago
ADAP new 52 week low
πŸ‘οΈ0
jondoeuk jondoeuk 9 months ago
Q2 results https://finance.yahoo.com/news/adaptimmune-reports-second-quarter-financial-112900334.html

BLA completion moved to Q4. PRAME IND also pushed forward to later this year (I guess Q4 as well). Nothing on lete-cel (NY-ESO-1). Also, SURPASS data at ESMO in October. However, the CMO said there would be only a few more monotherapy patients, with early data in around ten (across all indications) in combination with Opdivo. Sounds like expectations are low as he added, "remember that this is also in late stage patients who have been heavily pre-treated.'' Apart from that it's all good!
πŸ‘οΈ0
Monksdream Monksdream 9 months ago
ADAP new 52 week low
πŸ‘οΈ0
jondoeuk jondoeuk 10 months ago
πŸ‘‰Innovative new cell therapy approach makes its clinical debut: Integration of a CAR binding domain into the native TCR signaling complex (TRuC CAR) is associated with objective antitumor responses + on-target toxicities in mesothelin-expressing cancers. https://t.co/ZUG8jtMSpS— Klebanoff_Lab (@KlebanoffLab) July 27, 2023
πŸ‘οΈ0
Monksdream Monksdream 10 months ago
ADAP new 52 week low
πŸ‘οΈ0
jondoeuk jondoeuk 11 months ago
It's now recruiting.
πŸ‘οΈ0
jondoeuk jondoeuk 11 months ago
(OT): Combination of NY-ESO-1 TCR-T cells co-engineered to secrete SIRP-alpha decoys with antitumour antibodies to augment macrophage phagocytosis https://www.biorxiv.org/content/10.1101/2023.06.27.546523v1
πŸ‘οΈ0
jondoeuk jondoeuk 11 months ago
(OT): Interesting approach. I wonder if the efficacy could be improved by altering the phenotype of the recruited M2-like macrophages https://www.biorxiv.org/content/10.1101/2023.06.20.545790v1
πŸ‘οΈ0
jondoeuk jondoeuk 11 months ago
Case report https://journals.lww.com/melanomaresearch/Fulltext/9900/Durable_control_of_metastases_in_an_HLA_A2_.63.aspx

They should have continued with this sub-study https://d1io3yog0oux5.cloudfront.net/adaptimmune/files/pages/adaptimmune/db/336/description/DP006-21A_Adaptimmune_SITC_2021_Welsh_Radiation_Substudy_Poster_final.pdf
πŸ‘οΈ0
jondoeuk jondoeuk 12 months ago
Adaptimmune Announces 70% of People with Advanced Synovial Sarcoma Who Respond to Afami-cel are Alive Two Years Post-Treatment; Data from Cohort 1 of SPEARHEAD-1 to be Presented at ASCO https://finance.yahoo.com/news/adaptimmune-announces-70-people-advanced-210000466.html
πŸ‘οΈ0
jondoeuk jondoeuk 1 year ago
ASCO

The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Analysis of overall survival in advanced synovial sarcoma https://meetings.asco.org/abstracts-presentations/219898

The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Pooled analysis of cytokine release syndrome across cohorts in patients with advanced synovial sarcoma https://meetings.asco.org/abstracts-presentations/224954
πŸ‘οΈ0
jondoeuk jondoeuk 1 year ago
From FB https://www.fiercepharma.com/pharma/astellas-writes-340m-fibrogens-evrenzo-joins-gsk-nixing-cell-therapy-collab-adaptimmune

''In another R&D rewinding, Astellas is ending a partnership with Adaptimmune Therapeutics around stem cell-derived, off-the-shelf T cell therapies. The termination deals another blow to Adaptimmune as GSK just walked away from their cell therapy collaboration as well.''
πŸ‘οΈ0
jondoeuk jondoeuk 1 year ago
The company said it will regain rights to the PRAME and NY-ESO-1 programs from GSK. Adaptimmune will receive an upfront payment plus milestone-based payments totalling £30M related to the transfer of the clinical trials for the NY-ESO-1 programs.

The companies will transition materials and data related to the preclinical PRAME targeted TCR T-cell therapy program to Adaptimmune during 2023. The companies are targeting transfer of sponsorship for GSK's IGNYTE-ESO trial (NCT03967223) and long-term follow-up (NCT03391778) during Q3. The companies noted that all other trials within the NY-ESO-1 targeting program are already closed to enrollment and have already been or will soon be completed by GSK.
πŸ‘οΈ0
jondoeuk jondoeuk 1 year ago
Upcoming https://annualmeeting.asgct.org/program/agenda-details?agendaId=26880
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock